• Jay S Shavadia, Jonathan Wilson, Daniel Edmonston, Alyssa Platt, Patti Ephraim, Rasheeda Hall, Benjamin A Goldstein, L Ebony Boulware, Eric Peterson, Jane Pendergast, and Julia J Scialla.
• Department of Medicine, Division of Cardiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; Duke Clinical Research Institute, Durham, NC. Electronic address: jss372@usask.ca.
• Am. Heart J. 2021 Jan 1; 231: 36-44.

AbstractStatins failed to reduce cardiovascular (CV) events in trials of patients on dialysis. However, trial populations used criteria that often excluded those with atherosclerotic heart disease (ASHD), in whom statins have the greatest benefit, and included outcome composites with high rates of nonatherosclerotic CV events that may not be modified by statins. Here, we study whether statin use associates with lower atherosclerotic CV risk among patients with known ASHD on dialysis, including in those likely to receive a kidney transplant, a group excluded within trials but with lower competing mortality risks.Copyright © 2020 Elsevier Inc. All rights reserved.

27 keywords...

hide…